Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-12-30

AUTHORS

Moshe Rogosnitzky, Milton J. Finegold, Patricia J. McLaughlin, Ian S. Zagon

ABSTRACT

Hepatoblastoma is the most common liver malignancy in children, typically diagnosed before age 2. The survival rate for hepatoblastoma has increased dramatically in the last 30 years, but the typical chemotherapeutic agents used for treatment are associated with significant toxicity. In this report, the authors present two cases of hepatoblastoma treated with surgical resection and a novel biotherapeutic regimen that included opioid growth factor (OGF). Case #1 is an infant diagnosed with a large mass on prenatal ultrasound. After subsequent diagnosis of hepatoblastoma, she was treated with one course of neoadjuvant chemotherapy at approximately 1 week of age. Following significant complications from the chemotherapy (neutropenic fever, pneumonia and sepsis), the patient’s parents declined further chemotherapy, and the infant was treated with surgical resection and opioid growth factor (OGF)/low dose naltrexone (LDN). She is currently at close to 10 years disease–free survival. Case #2 is a child diagnosed with a liver mass on ultrasound at 20 months of age, later biopsy-proven to represent hepatoblastoma. Due to existing co-morbidities including autosomal recessive polycystic kidney disease and hypertension, and indications from the biopsy that the tumor might be insensitive to chemotherapy, the parents elected not to proceed with neoadjuvant chemotherapy. The patient was treated with surgical resection and OGF/LDN, and is currently at more than 5 years disease-free survival. This case series highlights the need for less toxic treatment options than conventional chemotherapy. Modulation of the OGF-OGF receptor axis represents a promising safe and therapeutic avenue for effective treatment of hepatoblastoma. More... »

PAGES

1066-1070

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-012-9918-3

DOI

http://dx.doi.org/10.1007/s10637-012-9918-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034054625

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23275062


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enkephalin, Methionine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatoblastoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infant, Newborn", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Opioid Peptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pregnancy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ultrasonography", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "MedInsight Research Institute, P.O. Box 386, 90840, Telz Stone, Israel", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "MedInsight Research Institute, P.O. Box 386, 90840, Telz Stone, Israel"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rogosnitzky", 
        "givenName": "Moshe", 
        "id": "sg:person.01140245157.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140245157.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, Texas Children\u2019s Cancer Center at Baylor College, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.39382.33", 
          "name": [
            "Department of Pathology, Texas Children\u2019s Cancer Center at Baylor College, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Finegold", 
        "givenName": "Milton J.", 
        "id": "sg:person.014103516477.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014103516477.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Neural & Behavioral Science, The Pennsylvania State University, College of Medicine, 17033, Hershey, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.29857.31", 
          "name": [
            "Department of Neural & Behavioral Science, The Pennsylvania State University, College of Medicine, 17033, Hershey, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McLaughlin", 
        "givenName": "Patricia J.", 
        "id": "sg:person.0643466344.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643466344.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Neural & Behavioral Science, The Pennsylvania State University, College of Medicine, 17033, Hershey, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.29857.31", 
          "name": [
            "Department of Neural & Behavioral Science, The Pennsylvania State University, College of Medicine, 17033, Hershey, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zagon", 
        "givenName": "Ian S.", 
        "id": "sg:person.01252226625.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252226625.58"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-004-0929-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013574058", 
          "https://doi.org/10.1007/s00280-004-0929-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.2007.01045.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038741753", 
          "https://doi.org/10.1111/j.1572-0241.2007.01045.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-14504-9_3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005591676", 
          "https://doi.org/10.1007/978-3-642-14504-9_3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-005-1028-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029040320", 
          "https://doi.org/10.1007/s00280-005-1028-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-12-30", 
    "datePublishedReg": "2012-12-30", 
    "description": "Hepatoblastoma is the most common liver malignancy in children, typically diagnosed before age 2. The survival rate for hepatoblastoma has increased dramatically in the last 30\u00a0years, but the typical chemotherapeutic agents used for treatment are associated with significant toxicity. In this report, the authors present two cases of hepatoblastoma treated with surgical resection and a novel biotherapeutic regimen that included opioid growth factor (OGF). Case #1 is an infant diagnosed with a large mass on prenatal ultrasound. After subsequent diagnosis of hepatoblastoma, she was treated with one course of neoadjuvant chemotherapy at approximately 1\u00a0week of age. Following significant complications from the chemotherapy (neutropenic fever, pneumonia and sepsis), the patient\u2019s parents declined further chemotherapy, and the infant was treated with surgical resection and opioid growth factor (OGF)/low dose naltrexone (LDN). She is currently at close to 10\u00a0years disease\u2013free survival. Case #2 is a child diagnosed with a liver mass on ultrasound at 20\u00a0months of age, later biopsy-proven to represent hepatoblastoma. Due to existing co-morbidities including autosomal recessive polycystic kidney disease and hypertension, and indications from the biopsy that the tumor might be insensitive to chemotherapy, the parents elected not to proceed with neoadjuvant chemotherapy. The patient was treated with surgical resection and OGF/LDN, and is currently at more than 5\u00a0years disease-free survival. This case series highlights the need for less toxic treatment options than conventional chemotherapy. Modulation of the OGF-OGF receptor axis represents a promising safe and therapeutic avenue for effective treatment of hepatoblastoma.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10637-012-9918-3", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "keywords": [
      "opioid growth factor", 
      "year disease-free survival", 
      "disease-free survival", 
      "surgical resection", 
      "neoadjuvant chemotherapy", 
      "growth factor", 
      "autosomal recessive polycystic kidney disease", 
      "toxic treatment options", 
      "recessive polycystic kidney disease", 
      "common liver malignancy", 
      "cases of hepatoblastoma", 
      "months of age", 
      "weeks of age", 
      "polycystic kidney disease", 
      "non-toxic treatment", 
      "typical chemotherapeutic agents", 
      "further chemotherapy", 
      "dose naltrexone", 
      "case series", 
      "liver malignancies", 
      "significant complications", 
      "kidney disease", 
      "treatment options", 
      "receptor axis", 
      "conventional chemotherapy", 
      "subsequent diagnosis", 
      "patient's parents", 
      "liver mass", 
      "effective treatment", 
      "prenatal ultrasound", 
      "chemotherapy", 
      "survival rate", 
      "therapeutic avenues", 
      "hepatoblastoma", 
      "chemotherapeutic agents", 
      "resection", 
      "significant toxicity", 
      "age 2", 
      "infants", 
      "treatment", 
      "survival", 
      "ultrasound", 
      "age", 
      "children", 
      "hypertension", 
      "regimen", 
      "complications", 
      "naltrexone", 
      "patients", 
      "biopsy", 
      "malignancy", 
      "large mass", 
      "tumors", 
      "factors", 
      "parents", 
      "disease", 
      "diagnosis", 
      "cases", 
      "weeks", 
      "months", 
      "toxicity", 
      "indications", 
      "report", 
      "LDN", 
      "options", 
      "years", 
      "agents", 
      "course", 
      "mass", 
      "modulation", 
      "rate", 
      "need", 
      "axis", 
      "series", 
      "avenues", 
      "authors"
    ], 
    "name": "Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment", 
    "pagination": "1066-1070", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034054625"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-012-9918-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23275062"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-012-9918-3", 
      "https://app.dimensions.ai/details/publication/pub.1034054625"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_554.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10637-012-9918-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9918-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9918-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9918-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9918-3'


 

This table displays all metadata directly associated to this object as RDF triples.

228 TRIPLES      21 PREDICATES      117 URIs      105 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-012-9918-3 schema:about N00386e7e3de345ebb5bf42cc1c38d4a2
2 N0fbeade91f8a4afda8560e00ebf2589d
3 N17012eb521634afca19df8acc8061b08
4 N1848158fe1db4e6f8f8c7b024ae5b2d8
5 N3536bddf407a4308adbb90f6e0a5c1cd
6 N4822a83ee91442179b516b48d758b69e
7 N560c068c573b44fe87d09505bce77dfc
8 N7ee1dd162ff34a79b438171936368d80
9 N839b910db5e2495fa81a70efd17a3843
10 N91c1c6ecc29a45908fc022fb196138e7
11 Na4f474d28351468f9f391519c6c212b2
12 Ne047c2fd4a8a4f5193295b224db7079c
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author N051c238dddee466e853ac653f9cfb897
16 schema:citation sg:pub.10.1007/978-3-642-14504-9_3
17 sg:pub.10.1007/s00280-004-0929-4
18 sg:pub.10.1007/s00280-005-1028-x
19 sg:pub.10.1111/j.1572-0241.2007.01045.x
20 schema:datePublished 2012-12-30
21 schema:datePublishedReg 2012-12-30
22 schema:description Hepatoblastoma is the most common liver malignancy in children, typically diagnosed before age 2. The survival rate for hepatoblastoma has increased dramatically in the last 30 years, but the typical chemotherapeutic agents used for treatment are associated with significant toxicity. In this report, the authors present two cases of hepatoblastoma treated with surgical resection and a novel biotherapeutic regimen that included opioid growth factor (OGF). Case #1 is an infant diagnosed with a large mass on prenatal ultrasound. After subsequent diagnosis of hepatoblastoma, she was treated with one course of neoadjuvant chemotherapy at approximately 1 week of age. Following significant complications from the chemotherapy (neutropenic fever, pneumonia and sepsis), the patient’s parents declined further chemotherapy, and the infant was treated with surgical resection and opioid growth factor (OGF)/low dose naltrexone (LDN). She is currently at close to 10 years disease–free survival. Case #2 is a child diagnosed with a liver mass on ultrasound at 20 months of age, later biopsy-proven to represent hepatoblastoma. Due to existing co-morbidities including autosomal recessive polycystic kidney disease and hypertension, and indications from the biopsy that the tumor might be insensitive to chemotherapy, the parents elected not to proceed with neoadjuvant chemotherapy. The patient was treated with surgical resection and OGF/LDN, and is currently at more than 5 years disease-free survival. This case series highlights the need for less toxic treatment options than conventional chemotherapy. Modulation of the OGF-OGF receptor axis represents a promising safe and therapeutic avenue for effective treatment of hepatoblastoma.
23 schema:genre article
24 schema:isAccessibleForFree false
25 schema:isPartOf N59ad32b39d544162992a1c4d318a8380
26 N8df4288194354944a41f589fe5913d92
27 sg:journal.1094201
28 schema:keywords LDN
29 age
30 age 2
31 agents
32 authors
33 autosomal recessive polycystic kidney disease
34 avenues
35 axis
36 biopsy
37 case series
38 cases
39 cases of hepatoblastoma
40 chemotherapeutic agents
41 chemotherapy
42 children
43 common liver malignancy
44 complications
45 conventional chemotherapy
46 course
47 diagnosis
48 disease
49 disease-free survival
50 dose naltrexone
51 effective treatment
52 factors
53 further chemotherapy
54 growth factor
55 hepatoblastoma
56 hypertension
57 indications
58 infants
59 kidney disease
60 large mass
61 liver malignancies
62 liver mass
63 malignancy
64 mass
65 modulation
66 months
67 months of age
68 naltrexone
69 need
70 neoadjuvant chemotherapy
71 non-toxic treatment
72 opioid growth factor
73 options
74 parents
75 patient's parents
76 patients
77 polycystic kidney disease
78 prenatal ultrasound
79 rate
80 receptor axis
81 recessive polycystic kidney disease
82 regimen
83 report
84 resection
85 series
86 significant complications
87 significant toxicity
88 subsequent diagnosis
89 surgical resection
90 survival
91 survival rate
92 therapeutic avenues
93 toxic treatment options
94 toxicity
95 treatment
96 treatment options
97 tumors
98 typical chemotherapeutic agents
99 ultrasound
100 weeks
101 weeks of age
102 year disease-free survival
103 years
104 schema:name Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment
105 schema:pagination 1066-1070
106 schema:productId N3f5f0bd0af25415c887a8b10bb111b1c
107 N877fed17a9a24d4c82aef5c5105bba4c
108 Nca2628011fb0447faa413cb2af11a1e7
109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034054625
110 https://doi.org/10.1007/s10637-012-9918-3
111 schema:sdDatePublished 2022-12-01T06:29
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher N55e1f28638f84bc485e891f94698fb32
114 schema:url https://doi.org/10.1007/s10637-012-9918-3
115 sgo:license sg:explorer/license/
116 sgo:sdDataset articles
117 rdf:type schema:ScholarlyArticle
118 N00386e7e3de345ebb5bf42cc1c38d4a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Opioid Peptides
120 rdf:type schema:DefinedTerm
121 N051c238dddee466e853ac653f9cfb897 rdf:first sg:person.01140245157.62
122 rdf:rest Nb254598c125448d4ba9e174b88ed55f7
123 N0fbeade91f8a4afda8560e00ebf2589d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Enkephalin, Methionine
125 rdf:type schema:DefinedTerm
126 N154ed10ec8524444bb9c6c97ab0e0193 rdf:first sg:person.0643466344.84
127 rdf:rest Nb7c91fb29b8a40dca1403efec767ae8e
128 N17012eb521634afca19df8acc8061b08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Pregnancy
130 rdf:type schema:DefinedTerm
131 N1848158fe1db4e6f8f8c7b024ae5b2d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Ultrasonography
133 rdf:type schema:DefinedTerm
134 N3536bddf407a4308adbb90f6e0a5c1cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Humans
136 rdf:type schema:DefinedTerm
137 N3f5f0bd0af25415c887a8b10bb111b1c schema:name dimensions_id
138 schema:value pub.1034054625
139 rdf:type schema:PropertyValue
140 N4822a83ee91442179b516b48d758b69e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Infant
142 rdf:type schema:DefinedTerm
143 N55e1f28638f84bc485e891f94698fb32 schema:name Springer Nature - SN SciGraph project
144 rdf:type schema:Organization
145 N560c068c573b44fe87d09505bce77dfc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Female
147 rdf:type schema:DefinedTerm
148 N59ad32b39d544162992a1c4d318a8380 schema:volumeNumber 31
149 rdf:type schema:PublicationVolume
150 N7ee1dd162ff34a79b438171936368d80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Chemotherapy, Adjuvant
152 rdf:type schema:DefinedTerm
153 N839b910db5e2495fa81a70efd17a3843 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Hepatoblastoma
155 rdf:type schema:DefinedTerm
156 N877fed17a9a24d4c82aef5c5105bba4c schema:name doi
157 schema:value 10.1007/s10637-012-9918-3
158 rdf:type schema:PropertyValue
159 N8df4288194354944a41f589fe5913d92 schema:issueNumber 4
160 rdf:type schema:PublicationIssue
161 N91c1c6ecc29a45908fc022fb196138e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Child
163 rdf:type schema:DefinedTerm
164 Na4f474d28351468f9f391519c6c212b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Infant, Newborn
166 rdf:type schema:DefinedTerm
167 Nb254598c125448d4ba9e174b88ed55f7 rdf:first sg:person.014103516477.24
168 rdf:rest N154ed10ec8524444bb9c6c97ab0e0193
169 Nb7c91fb29b8a40dca1403efec767ae8e rdf:first sg:person.01252226625.58
170 rdf:rest rdf:nil
171 Nca2628011fb0447faa413cb2af11a1e7 schema:name pubmed_id
172 schema:value 23275062
173 rdf:type schema:PropertyValue
174 Ne047c2fd4a8a4f5193295b224db7079c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Child, Preschool
176 rdf:type schema:DefinedTerm
177 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
178 schema:name Medical and Health Sciences
179 rdf:type schema:DefinedTerm
180 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
181 schema:name Clinical Sciences
182 rdf:type schema:DefinedTerm
183 sg:journal.1094201 schema:issn 0167-6997
184 1573-0646
185 schema:name Investigational New Drugs
186 schema:publisher Springer Nature
187 rdf:type schema:Periodical
188 sg:person.01140245157.62 schema:affiliation grid-institutes:None
189 schema:familyName Rogosnitzky
190 schema:givenName Moshe
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140245157.62
192 rdf:type schema:Person
193 sg:person.01252226625.58 schema:affiliation grid-institutes:grid.29857.31
194 schema:familyName Zagon
195 schema:givenName Ian S.
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252226625.58
197 rdf:type schema:Person
198 sg:person.014103516477.24 schema:affiliation grid-institutes:grid.39382.33
199 schema:familyName Finegold
200 schema:givenName Milton J.
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014103516477.24
202 rdf:type schema:Person
203 sg:person.0643466344.84 schema:affiliation grid-institutes:grid.29857.31
204 schema:familyName McLaughlin
205 schema:givenName Patricia J.
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643466344.84
207 rdf:type schema:Person
208 sg:pub.10.1007/978-3-642-14504-9_3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005591676
209 https://doi.org/10.1007/978-3-642-14504-9_3
210 rdf:type schema:CreativeWork
211 sg:pub.10.1007/s00280-004-0929-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013574058
212 https://doi.org/10.1007/s00280-004-0929-4
213 rdf:type schema:CreativeWork
214 sg:pub.10.1007/s00280-005-1028-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1029040320
215 https://doi.org/10.1007/s00280-005-1028-x
216 rdf:type schema:CreativeWork
217 sg:pub.10.1111/j.1572-0241.2007.01045.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1038741753
218 https://doi.org/10.1111/j.1572-0241.2007.01045.x
219 rdf:type schema:CreativeWork
220 grid-institutes:None schema:alternateName MedInsight Research Institute, P.O. Box 386, 90840, Telz Stone, Israel
221 schema:name MedInsight Research Institute, P.O. Box 386, 90840, Telz Stone, Israel
222 rdf:type schema:Organization
223 grid-institutes:grid.29857.31 schema:alternateName Department of Neural & Behavioral Science, The Pennsylvania State University, College of Medicine, 17033, Hershey, PA, USA
224 schema:name Department of Neural & Behavioral Science, The Pennsylvania State University, College of Medicine, 17033, Hershey, PA, USA
225 rdf:type schema:Organization
226 grid-institutes:grid.39382.33 schema:alternateName Department of Pathology, Texas Children’s Cancer Center at Baylor College, 77030, Houston, TX, USA
227 schema:name Department of Pathology, Texas Children’s Cancer Center at Baylor College, 77030, Houston, TX, USA
228 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...